共 41 条
[1]
Modlin I., Sandor A., An analysis of 8305 cases of carcinoid tumors, Cancer, 79, pp. 813-829, (1997)
[2]
Moertel C., Karnofsky memorial lecture. An odyssey in the land of small tumors, J Clin Oncol, 5, pp. 1502-1522, (1987)
[3]
Tomassetti P., Migliori M., Simoni P., Et al., Diagnostic value of plasma chromogranin A in neuroendocrine tumours, Eur J Gastroenterol Hepatol, 13, pp. 55-58, (2001)
[4]
Stridsberg M., Oberg K., Li Q., Et al., Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours, J Endocrinol, 144, pp. 49-59, (1995)
[5]
Kvols L., Moertel C., O'Connell M., Et al., Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue, N Engl J Med, 315, pp. 663-666, (1986)
[6]
Kvols L., Buck M., Moertel C., Et al., Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995), Ann Intern Med, 107, pp. 162-168, (1987)
[7]
Rubin J., Ajani J., Schirmer W., Et al., Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J Clin Oncol, 17, pp. 600-606, (1999)
[8]
Que F., Nagorney D., Batts K., Et al., Hepatic resection for metastatic neuroendocrine carcinomas, Am J Surg, 169, pp. 36-42, (1995)
[9]
Denney W., Kemp Jr. W., Anthony L., Et al., Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease, J Am Coll Cardiol, 32, pp. 1017-1022, (1998)
[10]
Moller J., Connolly H., Rubin J., Et al., Factors associated with progression of carcinoid heart disease, N Engl J Med, 348, pp. 1005-1015, (2003)